MENLO PARK, Calif., Oct. 5, 2015 /PRNewswire/ -- Asterias Biotherapeutics, Inc. (NYSE MKT: AST), a leading biotechnology company in the emerging field of regenerative medicine, today announced that Jane Lebkowski, Ph.D., President Research and Development and Chief Scientific Officer, will present at the annual Partnering Forum, part of the Stem Cell Meeting on the Mesa on October 7, 2015, at 2:15 PM ET/11:15 AM PT. Dr. Lebkowski will discuss the progress to date for the Company's transformative technology platforms, AST-VAC1 and AST-VAC2, which address opportunities across multiple cancers, stages of cancer, and combinations therapies and AST-OPC1, which is focused on the treatment of spinal cord injury and other neurodegenerative diseases.
Co-hosted by the Alliance for Regenerative Medicine (ARM), the California Institute for Regenerative Medicine (CIRM) and the Sanford Consortium for Regenerative Medicine, the 2015 Stem Cell Meeting on the Mesa is a three-day conference featuring the program's two-day Partnering Forum, a Public Forum lecture and a full-day Scientific Symposium.
At the Partnering Forum, held October 7th and 8th, industry executives will lead in-depth, interactive panels and workshops to discuss critical commercial issues facing the sector today.
The nationally recognized Scientific Symposium, held October 9th at the Salk Institute for Biological Studies, will showcase leading academic research in the field of regenerative medicine and advanced therapies.
Stem Cell Meeting on the Mesa is expected to attract nearly 800 attendees, including leading cell therapy, gene therapy and tissue engineering companies, large pharma and biotech, industry investors and major academic research institutions.
The following are specific details regarding Asterias' presentation at the conference:
2015 Stem Cell Meeting on the Mesa – Partnering Forum
Wednesday, October 7th at 2:15 PM ET/11:15 AM PT
Estancia La Jolla Hotel & Spa, 9700 North Torrey Pines Road, La Jolla, CA 92037
A live video webcast of all company presentations will be available at: http://stemcellmeetingonthemesa.com/webcast/ and will also be published on ARM's website shortly after the event.
About Asterias Biotherapeutics
Asterias Biotherapeutics, Inc. (NYSE MKT: AST) is a leading biotechnology company in the emerging field of regenerative medicine. The Company's proprietary, industry leading platforms are based on its pluripotent stem cell and dendritic cell immunotherapy technologies. Asterias is focused on developing therapies to treat conditions in several medical areas where there is high unmet medical need and inadequate available therapies. AST-OPC1 (oligodendrocyte progenitor cells) is currently in a Phase 1/2a dose escalation clinical trial in spinal cord injury. AST-VAC1 (antigen-presenting autologous dendritic cells) has demonstrated promise in a Phase 2 study in acute myelogenous leukemia. AST-VAC2 (antigen-presenting allogeneic dendritic cells) represents a second generation, allogeneic approach to dendritic cell vaccines. Additional information about Asterias can be found at www.asteriasbiotherapeutics.com.
Statements pertaining to future financial and/or operating results, future growth in research, technology, clinical development, and potential opportunities for Asterias, along with other statements about the future expectations, beliefs, goals, plans, or prospects expressed by management constitute forward-looking statements. Any statements that are not historical fact (including, but not limited to statements that contain words such as "will," "believes," "plans," "anticipates," "expects," "estimates") should also be considered to be forward-looking statements. Forward-looking statements involve risks and uncertainties, including, without limitation, risks inherent in the development and/or commercialization of potential products, uncertainty in the results of clinical trials or regulatory approvals, need and ability to obtain future capital, and maintenance of intellectual property rights. Actual results may differ materially from the results anticipated in these forward-looking statements and as such should be evaluated together with the many uncertainties that affect the businesses of Asterias, particularly those mentioned in the cautionary statements found in Asterias' filings with the Securities and Exchange Commission. Asterias disclaims any intent or obligation to update these forward-looking statements.
SOURCE Asterias Biotherapeutics, Inc.